{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T03:53:41Z","timestamp":1768449221568,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s12325-022-02164-8","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T06:02:57Z","timestamp":1652421777000},"page":"3199-3213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews"],"prefix":"10.1007","volume":"39","author":[{"given":"Mark","family":"Gudesblatt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cortnee","family":"Roman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry A.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hollie","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai L.","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivani","family":"Kapadia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"key":"2164_CR1","doi-asserted-by":"crossref","first-page":"s53","DOI":"10.7861\/clinmedicine.16-6-s53","volume":"16","author":"A Doshi","year":"2016","unstructured":"Doshi A, Chataway J. Multiple sclerosis, a treatable disease. Clin Med (Lond). 2016;16:s53\u20139.","journal-title":"Clin Med (Lond)"},{"key":"2164_CR2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/WCO.0000000000000700","volume":"32","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Mares J, Hartung H-P. Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. Curr Opin Neurol. 2019;32:365\u201377.","journal-title":"Curr Opin Neurol"},{"key":"2164_CR3","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.msard.2017.10.001","volume":"18","author":"B Gerber","year":"2017","unstructured":"Gerber B, Cowling T, Chen G, Yeung M, Duquette P, Haddad P. The impact of treatment adherence on clinical and economic outcomes in multiple sclerosis: real world evidence from Alberta, Canada. Mult Scler Relat Disord. 2017;18:218\u201324.","journal-title":"Mult Scler Relat Disord"},{"key":"2164_CR4","doi-asserted-by":"crossref","first-page":"172","DOI":"10.7224\/1537-2073.2016-039","volume":"19","author":"C Mansfield","year":"2017","unstructured":"Mansfield C, Thomas N, Gebben D, Lucas M, Hauber AB. Preferences for multiple sclerosis treatments: using a discrete-choice experiment to examine differences across subgroups of US patients. Int J MS Care. 2017;19:172\u201383.","journal-title":"Int J MS Care"},{"key":"2164_CR5","unstructured":"VUMERITY\u00ae (diroximel fumarate) [Prescribing Information]. Cambridge, MA: Biogen Inc.; 2020."},{"key":"2164_CR6","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1177\/1352458519881761","volume":"26","author":"RT Naismith","year":"2020","unstructured":"Naismith RT, Wolinsky JS, Wundes A, et al. Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Mult Scler. 2020;26:1729\u201339.","journal-title":"Mult Scler"},{"key":"2164_CR7","doi-asserted-by":"crossref","first-page":"175628642091500","DOI":"10.1177\/1756286420915005","volume":"13","author":"R Gold","year":"2020","unstructured":"Gold R, Arnold DL, Bar-Or A, et al. Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years\u2019 follow-up of DEFINE, CONFIRM, and ENDORSE. Ther Adv Neurol Disord. 2020;13:1756286420915005.","journal-title":"Ther Adv Neurol Disord"},{"key":"2164_CR8","first-page":"205521731988719","volume":"5","author":"T Berger","year":"2019","unstructured":"Berger T, Brochet B, Brambilla L, et al. Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing\u2013remitting multiple sclerosis in a real-world clinical setting: PROTEC. Mult Scler J Exp Transl Clin. 2019;5:2055217319887191.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"2164_CR9","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/j.clinthera.2018.10.011","volume":"40","author":"K Kresa-Reahl","year":"2018","unstructured":"Kresa-Reahl K, Repovic P, Robertson D, Okwuokenye M, Meltzer L, Mendoza JP. Effectiveness of delayed-release dimethyl fumarate on clinical and patient-reported outcomes in patients with relapsing multiple sclerosis switching from glatiramer acetate: RESPOND, a prospective observational study. Clin Ther. 2018;40:2077\u201387.","journal-title":"Clin Ther"},{"key":"2164_CR10","doi-asserted-by":"crossref","first-page":"236","DOI":"10.7224\/1537-2073.2014-069","volume":"17","author":"JT Phillips","year":"2015","unstructured":"Phillips JT, Selmaj K, Gold R, et al. Clinical significance of gastrointestinal and flushing events in patients with multiple sclerosis treated with delayed-release dimethyl fumarate. Int J MS Care. 2015;17:236\u201343.","journal-title":"Int J MS Care"},{"key":"2164_CR11","doi-asserted-by":"crossref","first-page":"74","DOI":"10.7224\/1537-2073.2015-086","volume":"19","author":"JT Phillips","year":"2017","unstructured":"Phillips JT, Agrella S, Fox RJ. Dimethyl fumarate: a review of efficacy and practical management strategies for common adverse events in patients with multiple sclerosis. Int J MS Care. 2017;19:74\u201383.","journal-title":"Int J MS Care"},{"key":"2164_CR12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40120-021-00242-7","volume":"10","author":"J Liseno","year":"2021","unstructured":"Liseno J, Lager B, Miller C, Shankar SL, Mendoza JP, Lewin JB. Multiple sclerosis patients treated with diroximel fumarate in the real-world setting have high rates of persistence and adherence. Neurol Ther. 2021;10:349\u201360.","journal-title":"Neurol Ther."},{"key":"2164_CR13","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1007\/s12325-019-01085-3","volume":"36","author":"MJ Palte","year":"2019","unstructured":"Palte MJ, Wehr A, Tawa M, et al. Improving the gastrointestinal tolerability of fumaric acid esters: early findings on gastrointestinal events with diroximel fumarate in patients with relapsing-remitting multiple sclerosis from the phase 3, open-label EVOLVE-MS-1 study. Adv Ther. 2019;36:3154\u201365.","journal-title":"Adv Ther"},{"key":"2164_CR14","doi-asserted-by":"crossref","first-page":"175628642199399","DOI":"10.1177\/1756286421993999","volume":"14","author":"A Wundes","year":"2021","unstructured":"Wundes A, Wray S, Gold R, et al. Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. Ther Adv Neurol Disord. 2021;14:1756286421993999.","journal-title":"Ther Adv Neurol Disord"},{"key":"2164_CR15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s42466-020-00059-z","volume":"2","author":"L Busetto","year":"2020","unstructured":"Busetto L, Wick W, Gumbinger C. How to use and assess qualitative research methods. Neurol Res Pract. 2020;2:14.","journal-title":"Neurol Res Pract"},{"key":"2164_CR16","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1097\/ACM.0000000000000388","volume":"89","author":"BC O'Brien","year":"2014","unstructured":"O\u2019Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014;89:1245\u201351.","journal-title":"Acad Med"},{"key":"2164_CR17","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/nhs.12048","volume":"15","author":"M Vaismoradi","year":"2013","unstructured":"Vaismoradi M, Turunen H, Bondas T. Content analysis and thematic analysis: Implications for conducting a qualitative descriptive study. Nurs Health Sci. 2013;15:398\u2013405.","journal-title":"Nurs Health Sci"},{"key":"2164_CR18","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis. Report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2018;90:777\u201388.","journal-title":"Neurology"},{"key":"2164_CR19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/1756285614555335","volume":"7","author":"KS Utz","year":"2014","unstructured":"Utz KS, Hoog J, Wentrup A, et al. Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis. Ther Adv Neurol Disord. 2014;7:263\u201375.","journal-title":"Ther Adv Neurol Disord"},{"key":"2164_CR20","unstructured":"Biogen. Avonex (interferon beta-1a) Prescribing Information. 2020. https:\/\/www.avonex.com\/content\/dam\/commercial\/avonex\/pat\/en_us\/pdf\/Avonex_US_Prescribing_Information.pdf. Accessed 22 Feb 2021."},{"key":"2164_CR21","unstructured":"Teva. Copaxone (glatiramer acetate) Prescribing Information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/020622s102lbl.pdf. Accessed 22 Feb 2021."},{"key":"2164_CR22","unstructured":"Genentech. Ocrevus (ocrelizumab) Prescribing Information. 2021. https:\/\/www.gene.com\/download\/pdf\/ocrevus_prescribing.pdf. Accessed 21 Apr 2021."},{"key":"2164_CR23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40120-015-0037-x","volume":"4","author":"J Theodore Phillips","year":"2015","unstructured":"Theodore Phillips J, Erwin AA, Agrella S, et al. Consensus management of gastrointestinal events associated with delayed-release dimethyl fumarate: a Delphi study. Neurol Ther. 2015;4:137\u201346.","journal-title":"Neurol Ther"},{"key":"2164_CR24","doi-asserted-by":"crossref","first-page":"102512","DOI":"10.1016\/j.msard.2020.102512","volume":"46","author":"AC Vogel","year":"2020","unstructured":"Vogel AC, Schmidt H, Loud S, McBurney R, Mateen FJ. Impact of the COVID-19 pandemic on the health care of > 1,000 people living with multiple sclerosis: a cross-sectional study. Mult Scler Relat Disord. 2020;46:102512.","journal-title":"Mult Scler Relat Disord."},{"key":"2164_CR25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s40120-021-00241-8","volume":"10","author":"H Morris-Bankole","year":"2021","unstructured":"Morris-Bankole H, Ho AK. The COVID-19 pandemic experience in multiple sclerosis: the good, the bad and the neutral. Neurol Ther. 2021;10:279\u201391.","journal-title":"Neurol Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02164-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02164-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02164-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T19:02:36Z","timestamp":1656442956000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02164-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["2164"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02164-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,13]]},"assertion":[{"value":"13 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}